



003 Rec'd PCT/PTO 1 1 APR 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. GJE-6758
Serial No. 10/519,594

April 8, 2005

David Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : Not yet assigned
Applicant(s) : David Cavalla and Robert William Gristwood
Serial No. : 10/519,594
Filed : December 28, 2004
Conf. No. : Not yet assigned
For : New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno
[2,3-D]Pyrimidine

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

The above-identified patent application was filed in the U.S. Patent Office as a national application under 35 USC §371. A copy of the International Search Report and copies of the references cited therein have been made available in the national stage file.


However, for the examiner's convenience, the applicants are attaching a copy of the International Search Report as well as copies of the documents cited in the International Search Report. Also attached is Form PTO/SB/08 listing the references.

Please note that DE 100 63 223 is in a foreign language. The applicants have attached CA 2431074, which is a corresponding application for the Examiner's convenience.

In accordance with 37 CFR §1.56, applicants hereby request that the references cited in the international search report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100


Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

DRS/la

Attachments: Form PTO/SB/08;
International Search Report; and
Copy of documents listed on form PTO/SB/08



Place a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 1			Complete if Known	
			Application Number	10/519,594
			Filing Date	December 28, 2004
			First Named Inventor	David Cavalla
			Group Art Unit	Not yet assigned
			Examiner Name	Not yet assigned
			Attorney Docket Number	GJE-6758

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1	6,284,770		Mangel <i>et al.</i>	09-04-2001	
	U2	4,695,568		Ninomiya <i>et al.</i>	09-22-1987	
	U3					
	U4					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	F1		CA 2431074		Merck Patent GMBH	06-27-2002		
	F2		DE 100 63 223		GMBH	06-20-2002		
	F3							
	F4							
	F5							
	F7							
	F8							

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	CROWELL M. D., "The Role of Serotonin in the Pathophysiology of Irritable Bowel Syndrome," <i>American Journal of Managed Care</i> , 2001, 7:S252-S260.	
	R2	EGUCHI J. <i>et al.</i> , "The Anxiolytic-like Effect of MCI-225, a Selective NA Reuptake Inhibitor With 5-HT ₃ Receptor Antagonism," <i>Pharmacology, Biochemistry and Behavior</i> , 2000, 68:677-683.	
	R3		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.